Table 1 Baseline characteristics by frailty status
| All patients (n = 198) | Not frail (CFS 1–4) (n = 158) | Frail (CFS 5–9) (n = 40) | |
|---|---|---|---|
| Age, years (mean, SD) | 79 (6) | 78 (6) | 83 (7) |
| Male | 115 (58) | 99 (63) | 16 (40) |
| Primary diagnosis | |||
| Non-ST segment elevation myocardial infarction | 151 (76) | 122 (77) | 29 (73) |
| ST-segment elevation myocardial infarction | 47 (24) | 36 (23) | 11 (28) |
| Past medical history | |||
| Heart failure | 36 (18) | 21 (13) | 15 (38) |
| Stroke | 35 (18) | 25 (16) | 10 (25) |
| Diabetes mellitus | 35 (18) | 32 (20) | 3 (8) |
| Chronic kidney disease (stage III or worse) | 45 (23) | 30 (19) | 15 (38) |
| Peripheral vascular disease | 28 (14) | 21 (13) | 7 (18) |
| Chronic respiratory disease | 39 (20) | 25 (16) | 14 (35) |
| Dementia | 14 (7) | 7 (4) | 7 (18) |
| Current or ex-smoker | 118 (60) | 96 (61) | 22 (55) |
| Medications at recruitment | |||
| Total number prescribed drugs (mean, SD) | 9.2 (3.1) | 8.9 (3.1) | 10.5 (2.9) |
| Aspirin | 178 (90) | 144 (91) | 34 (85) |
| Clopidogrel | 183 (92) | 145 (92) | 38 (95) |
| ACE-inhibitor or ARB | 127 (64) | 113 (72) | 14 (35) |
| Diuretic | 80 (40) | 57 (36) | 23 (58) |
| Beta-blocker | 118 (60) | 98 (62) | 20 (50) |
| Statin | 155 (78) | 132 (84) | 23 (58) |
| Oral anticoagulant | 26 (13) | 22 (14) | 4 (10) |
| Laboratory measures | |||
| Haemoglobin, g/L (mean, SD) | 13.1 (1.8) | 13.1 (1.8) | 12.7 (2.0) |
| Creatinine, μmol/L (mean, SD) | 104 (45) | 101 (39) | 119 (62) |
| Estimated GFR, ml/min/1.73 m2 (mean, SD) | 62 (24) | 65 (23) | 54 (24) |
| Risk and functional measures | |||
| GRACE 2 12-month mortality (mean, SD) | 18.5 (13.2) | 16.2 (11.7) | 27.8 (15.0) |
| Charlson comorbidity index (mean, SD) | 2.9 (1.8) | 2.6 (1.6) | 3.9 (2.2) |
| Karnofsky scale score (mean, SD) | 78.5 (17.1) | 84.6 (11.8) | 54.5 (13.0) |